Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 42
- Registration Number
- NCT05232071
- Locations
- 🇺🇸
Birmingham Digestive Health Research, Homewood, Alabama, United States
🇺🇸Institute for Liver Health dba Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Cure Clinical Research, LLC, Fountain Valley, California, United States
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 1000
- Registration Number
- NCT04849728
- Locations
- 🇺🇸
Mercy Medical Center - Mcauley Plaza, Baltimore, Maryland, United States
🇺🇸National Research Institute - Westlake, Los Angeles, California, United States
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 36
- Registration Number
- NCT03866369
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Study in MPS VI to Assess Safety and Efficacy of Odiparcil
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT03370653
- Locations
- 🇫🇷
Hôpital Femme-Mère-Enfant, Bron, France
🇬🇧Royal Free Hospital, London, United Kingdom
🇵🇹Centro Hospitalar S. João, Porto, Portugal
Phase 2b Study in NASH to Assess IVA337
- Conditions
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 247
- Registration Number
- NCT03008070
- Locations
- 🇧🇪
Hopital Erasme, Brussels, Belgium
🇵🇱Klinika Chorób Zakaźnych, Lublin, Poland
🇸🇮General Hospital Murska Sobota, Murska Sobota, Slovenia
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 145
- Registration Number
- NCT02503644
- Locations
- 🇧🇬
University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski, Pleven, Bulgaria
🇧🇬Multiprofile Hospital for Active Treatment Plovdiv, Plovdiv, Bulgaria
🇫🇷Hôpital Pellegrin, Bordeaux, France